✦ LIBER ✦

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series

✍ Scribed by Zagouri, F; Sergentanis, T N; Koutoulidis, V; Sparber, C; Steger, G G; Dubsky, P; Zografos, G C; Psaltopoulou, T; Gnant, M; Dimopoulos, M-A; Bartsch, R

Book ID: 120426131
Publisher: Nature Publishing Group
Year: 2013
Tongue: English
Weight: 224 KB
Volume: 108
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.2013.255

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The luteinising hormone–releasing hormon

The luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers

✍ Antonia Martinetti; Leonardo Ferrari; Luigi Celio; Luigi Mariani; Rosalba Miceli 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 112 KB

A luteinizing hormone-releasing hormone

A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer

✍ Tanaka, Kimihiro; Tokunaga, Eriko; Yamashita, Nami; Taketani, Kenji; Akiyoshi, S 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 204 KB

A randomised study to compare the effect

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer

✍ W. Jonat; M. Kaufmann; R.W. Blamey; A. Howell; J.P. Collins; A. Coates; W. Eierm 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 587 KB

691 - The LHRH analogue triptoreline (TA

691 - The LHRH analogue triptoreline (TAP) with or without the aromatase inhibitor formestane (4-OHA) in premenopausal advanced breast cancer: A study by the I.T.M.O. group

✍ L. Celio; A. Martinetti; L. Ferrari; R. Buzzoni; E. Bombardieri; N. Zilembo; L. 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 257 KB

Fulvestrant plus anastrozole or placebo

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

✍ Johnston, Stephen RD; Kilburn, Lucy S; Ellis, Paul; Dodwell, David; Cameron, Dav 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 459 KB